

Product Name	: Saracatinib
Synonyms	: AZD0530;AZD-0530;AZD 0530
Cat No.	: M14308
CAS Number	: 379231-04-6
Molecular Formula	: C ₂₇ H ₃₂ ClN ₅ O ₅
Formula Weight	: 542.03
Chemical Name	: 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-
Description	: A potent, highly selective, orally available, dual Src/Abl kinase inhibitor with IC ₅₀ of 2.7, 4, 4 and 30 nM for c-Src, Yes, Lck and Abl, respectively; displays high selectivity over a range of kinases (Csk, VEGFR-2, Flt-4, EGFR, and PDGFR); exhibits potent inhibition of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo. Breast Cancer Phase 2 Clinical
Pathway	: Angiogenesis
Target	: Src
Receptor	: BLK;c-Kit;c-Src;c-Yes;EGFR;EGFR(L858R);EGFR(L861Q);EphA2;FGR;Fyn;Lck;Lyn;v-Abl;EGFR(L861Q);EGFR(L858R)
Solubility	: DMSO: ≥ 32 mg/mL
SMILES	: CN1CCN(CCOC2=CC3=NC=NC(NC4=C5OCOC5=CC=C4Cl)=C3C(OC6CCOCC6)=C2)CC1
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Hennequin LF, et al. J Med Chem. 2006 Nov 2;49(22):6465-88. | 2. Herynk MH, et al. Mol Cancer Ther. 2006 Dec;5(12):3023-31. | 3. Chang YM, et al. Oncogene. 2008 Oct 23;27(49):6365-75. | 4. Gwanmesia PM, et al. BMC Cancer. 2009 Feb 13;9:53.

